Ziprasidone
Ziprasidone is an antipsychotic medication belonging to the second-generation (atypical) antipsychotic class. It is primarily used to treat schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain, while also influencing serotonin and norepinephrine reuptake. This helps regulate neurotransmitter activity and reduce symptoms such as hallucinations, delusions, mood disturbances, and disorganised thinking. Ziprasidone is administered orally in capsule form and is also available as an intramuscular injection for acute agitation associated with schizophrenia. Common side effects include dizziness, drowsiness, nausea, headache, and restlessness. Serious adverse effects may include QT interval prolongation, abnormal heart rhythms, tardive dyskinesia, and neuroleptic malignant syndrome. It should be used under medical supervision, with particular attention to cardiac health and ECG monitoring when clinically indicated. Oral capsules should be taken with food to ensure adequate absorption.
Ziprasidone was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Ziprasidone, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Ziprasidone from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Ziprasidone, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
